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ABSTRACT 
 
The feasibility of topical application onto the (lower) eyelid skin to deliver 
hydrophilic and lipophilic compounds into the conjunctiva and ocular tissues was evaluated 
by comparing with conventional eye drop application. Skin permeation and the concentration 25 
of several model compounds, and skin impedance were determined utilizing eyelid skin from 
hairless rats, as well as abdominal skin in the same animals for comparison. In vitro static 
diffusion cells were used to assess the skin permeation in order to provide key insights into 
the relationship between the skin sites and drugs. The obtained results revealed that drug 
permeation through the eyelid skin was much higher than that through abdominal skin 30 
regardless of the drug lipophilicity. Specifically, diclofenac sodium salt and tranilast 
exhibited approximately 6-fold and 11-fold higher permeability coefficients, respectively, 
through eyelid skin compared with abdominal skin. Histomorphological evaluation and in 
vivo distribution of model fluorescent dyes were also examined in the conjunctiva and skin 
after eyelid administration by conventional microscope and confocal laser scanning 35 
microscope analyses. The result revealed that eyelid skin has a thinner stratum corneum, 
thereby showing lower impedance, which could be the reason for the higher drug permeation 
through eyelid skin. Comparative evaluation of lipophilic and hydrophilic model compounds 
administered via the eyelid skin over 8 h revealed stronger fluorescence intensity in the skin 
and surrounding tissues compared with eye drop administration. These results suggested that 40 
the (lower) eyelid skin is valuable as a prospective site for ophthalmic medicines.  
 
Chemical compounds used in this article: 
Aminopyrine (PubChem CID: 6009); Antipyrine (PubChem CID: 2206); Diclofenac sodium 
(PubChem CID: 5018304); Fluorescein sodium (PubChem CID: 9885981); Lidocaine 45 
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(PubChem CID: 3676); Pilocarpine hydrochloride (PubChem CID: 5909); Rhodamine B 
(PubChem CID: 6694); Tranilast (PubChem CID: 5282230) 
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1. INTRODUCTION 
For several decades, eye drops have remained one of the paramount and most 
extensively utilized pharmaceutical formulations for various ocular diseases (i.e., the eyeball 
and surrounding tissues) (Baranowski et al., 2014). Currently, eye drops account for about 90% 60 
of ophthalmic medicines, primarily due their to ease of administration and good patient 
compliance. However, several drawbacks are associated with the utilization of eye drops. Eye 
medications cannot be administered beyond the capacity of the conjunctival sac due to its 
limited volume. Most eye drops exhibit low bioavailability, poor targeting efficacy, and are 
virtually impossible to administer during sleep. Anatomical and physiological constrains such 65 
as tear turnover, nasolacrimal drainage, reflex blinking, and ocular static and dynamic 
barriers impede the bioavailability and controlled delivery of drugs administered as eye drops 
(Kimura et al., 2007; Gaudana et al., 2010; Isowaki et al., 2003; Gause et al., 2015). With 
these impediments, it is essential to search for an alternative approach to deliver ophthalmic 
drugs with high targeting ability while simultaneously improving drug absorption into the 70 
ocular tissues.  
We paid attention to applying and delivering ophthalmic drugs onto the (lower) eyelid 
skin using various formulations. The lower eyelid skin exhibits less movement due to blinks 
compared with the upper eyelid skin, making it a good site for administration. Moreover, it is 
very interesting for skin researchers to explore the eyelids, which is the thinnest skin layer on 75 
the human body (< 1 mm) (Amirlak and Sahshabi, 2015). Generally, the thinner the stratum 
corneum, the greater the drug permeation. In addition, drug administration through the skin 
provides several advantages because it generally facilitates avoidance of premature 
metabolism, decreased toxicity, fewer side effects as well as greater patient compliance 
(Paudel et al., 2010). 80 
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A unique feature of the eyelids from the drug delivery standpoint is their proximity to 
the conjunctiva, which is between 2 and 30 times more permeable to drugs than the cornea 
(Davies, 2000). It should be noted that the conjunctiva has direct contact with the eyeball and 
its surrounding ocular tissues. With the presence of drugs in the conjunctiva, it is expected to 
distribute into the anterior and posterior ocular regions, which is the delivery target area in 85 
most ocular diseases. In addition, transdermal drug delivery could maintain a constant drug 
concentration in the dermal layers beneath the application site for a longer duration. This is 
the most beneficial point compared with eye drops application, which has many drawbacks, 
as described above. If drugs could be delivered to the conjunctival tissue via the eyelid skin, 
these drawbacks associated with the eye drops could be addressed. Moreover, once 90 
medications are prepared for eyelid administration, greater convenience is obtained for 
patients with ocular diseases (i.e. allergic conjunctivitis, eye infections, glaucoma) and health 
care professionals alike. Time for drug administration by patients or health care professionals 
is reduced while treatment may continue even when the patient is asleep, thereby increasing 
drug retention time and consequently improving patient comfort and quality of life. 95 
With the limited number of studies investigating the delivery of drugs into the 
conjunctiva through eyelid skin and the paucity of data describing eyelid drug permeation, we 
were prompted to study hydrophilic and lipophilic model compounds and to compare 
permeability characteristics through the eyelid and the abdominal skin. In the present study, 
we selected hairless rats as a model animal, because it is more practical for conducting in vivo 100 
and in vitro experiments compared with other larger animal models. We believed that this is 
the first study on ophthalmic drug delivery utilizing rat eyelid skin. Pilocarpine hydrochloride, 
tranilast, antipyrine, diclofenac sodium, aminopyrine, and lidocaine were used to evaluate 
their skin permeation; the former two were used to evaluate the skin concentration, and two 
6 
fluorescent dyes (fluorescein sodium and rhodamine B) were used to determine the in vivo 105 
distribution of the drugs in the conjunctiva. 
 
2. MATERIALS AND METHODS 
2.1 Materials and Experimental Animals 
Pilocarpine hydrochloride was purchased from Sigma-Aldrich (St. Louis, MO, USA). 110 
Lidocaine and tranilast were purchased from Tokyo Chemical Industry Co. Ltd. (Tokyo, 
Japan). Aminopyrine, antipyrine, diclofenac sodium, fluorescein sodium, and rhodamine B 
were purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). Table 1 lists the 
chemicals used as model permeants and their physicochemical properties.  
Male hairless rats (WBM/ILA-Ht, 8 weeks of age, body weight of 220–260 g) were 115 
obtained from the Life Science Research Center, Josai University (Sakado, Saitama, Japan) 
or Ishikawa Experimental Animal Laboratories (Fukaya, Saitama, Japan). All animal feeding 
and experiments were approved by Institutional Animal Care and Use Committee of Josai 
University.  
2.2 Preparation of Skin Membranes 120 
Whole abdominal and (lower) eyelid skin were freshly excised from hairless rats 
previously shaved while anesthetized using three types of anesthesia (0.375 mg/kg 
medetomidine, 2.5 mg/kg butorphanol, 2 mg/kg midazolam) administered intraperitoneally. 
The excised skin was cleaned with pH 7.4 phosphate-buffered saline (PBS).  
2.3 Skin Permeation Experiments  125 
Skin permeation experiments were carried out using Franz type vertical diffusion cells. 
Excess subcutaneous fat was trimmed off from the excised intact abdominal skin and no 
trimming was done for eyelid skin. The eyelid skin was placed on a stabilizing apparatus with 
an effective diffusion area of 0.0707 cm2 before it was set in a vertical diffusion cell. The 
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abdominal skin sample was directly set in a vertical type diffusion cell with an effective 130 
diffusion area of 1.77 cm2. One mL of PBS, which corresponded to the donor solution and 
contained no permeant, was applied to the epidermis side and 6.0 mL of PBS was applied to 
the dermis side of the skin to reach an equilibration state for about 1 hour. After an hour, the 
PBS of the epidermis side was replaced with the same volume of the donor solution (model 
compounds dissolved in PBS) to commence the permeation experiment. The receiver solution 135 
was stirred with a stirrer bar on a magnetic stirrer and maintained at 32°C using a 
thermostatically controlled heater throughout the experiments. An aliquot (500 µL) was 
withdrawn from the receiver chamber and the same volume of fresh PBS was added to the 
chamber to keep the volume constant. The penetrant concentration in the receiver chamber 
was determined by HPLC. 140 
2.4 Determination of Skin Concentrations 
The concentrations of the compounds in intact rat skin were measured at 8 h after the 
start of the experiments, which were performed separately from the experiments mentioned 
above. The donor solution was removed, the stratum corneum side was rinsed three times 
with 1.0 mL of PBS, and the compound-applied area was cut out. When the concentrations in 145 
viable epidermis and dermis were measured, the stratum corneum was removed by tape-
stripping 20 times before clipping out the application area. The piece of skin was reduced in 
size using scissors, and 0.5 mL of PBS was added prior to homogenization at 12,000 rpm and 
4°C for 5 min using a homogenizer (Polytron PT 1200 E, Kinematica AG, Littaue-Lucerne, 
Switzerland). For deproteinization, 0.5 mL of 16% trichloroacetic acid in PBS was added to 150 
the skin homogenate, followed by agitation at 32°C for 15 min, and then the mixture was 
centrifuged at 15,000 rpm and 4°C for 5 min. The compound concentration in the resulting 
supernatant was determined by high-performance liquid chromatography (HPLC).  
2.5 HPLC Analysis 
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Samples were mixed with the same volume of acetonitrile containing the internal 155 
standard and centrifuged at 15,000 rpm and 4°C for 5 min. The obtained supernatant (20 µL) 
was injected into an HPLC system. The HPLC system (Shimadzu Co., Kyoto, Japan) 
consisted of a system controller (SCL-10A), pump (LC-20AD), degasser (DGU-20A3), auto-
injector (SIL-20A), column oven (CTO-20A), UV detector (SPD-20A) and analysis software 
(LC Solution). The column used was Inertsil® ODS-3 4.6 mm × 150 mm, 5 µm (GL Sciences 160 
Inc., Tokyo, Japan). The column was maintained at 40°C and the flow rate of the mobile 
phase was adjusted to 1.0 mL/min. Refer to Table 2 for the details of the HPLC conditions.  
2.6 Data Analysis 
The cumulative amount of model drugs permeated through the eyelid and the 
abdominal skin was calculated and expressed as the mean ± S.E. The permeation rate or flux 165 
(J, µg/cm2/h), 6–8 h after starting the experiment, was determined based on the slope of 
linear regression of the cumulative amount of the model drugs against permeation time.  
2.7 In Vivo Application Study 
In this study, three hairless rats were used. The left eye was designated for the model 
compound to be delivered through a tube simulating transdermal drug delivery, whereas the 170 
right eye was designated for the compound to be administered using drops simulating an eye 
drop. The rats were anesthetized with three types of anesthesia (0.375 mg/kg medetomidine, 
2.5 mg/kg butorphanol, 2 mg/kg midazolam) administered intraperitoneally for the duration 
of the sampling period. A Teflon tube (internal diameter 3 mm) was glued onto the left eyelid 
skin using cyanoacrylate bond (Aron Alpha, Konishi Co. Ltd., Osaka, Japan), but nothing 175 
was attached on the other side (Fig. 1). Ten microliters of the model compound (0.5 mM 
rhodamine B or 0.5 mM fluorescein sodium in PBS) was administered to each eye of the rat 
and rats were individually euthanized with pentobarbital sodium (100 mg/kg) 
intraperitoneally at each time point (10 min, 2 h, 8 h). After which, the (lower) eyelid skin 
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was excised from rats by making an incision in the skin of the cranium, peeled away towards 180 
the eyelids. At the palpebra, the skin was cut along the palpebral edge. The skin-free palpebra 
was then removed by cutting along the orbital arc (Maistrello et al., 1973). Thereafter, the 
excised rat lower eyelid skin was washed three times with 1.0 mL PBS on each side of the 
dermis and epidermis and kept at -30°C until further processing (skin sectioning).  
2.8 Measurement of Skin Impedance 185 
Excised hairless rat abdominal skin or eyelid skin (either for full-thickness or stripped 
skin) was placed between Franz diffusion cells. PBS was added to the stratum corneum and 
dermis sides. Skin impedance was determined using an impedance meter (10 Hz AC, Asahi 
Technolab, Tokyo, Japan).  
2.9 Histomorphological Observation of Under Eyelid and Abdominal Skin 190 
The skin samples, from hairless rat eyelid skin and abdominal skin, were cut vertically 
using a razor blade, embedded in supercryoembedding medium, and were allowed to freeze 
using isopentane, and cooled with dry ice. Skin slices (10 µm thickness) were made using a 
cryostat (CM3050, LEICA, Wetzler, Hessen, Germany). 
Hematoxylin and Eosin Staining. The obtained skin sections were stained with 195 
hematoxylin and eosin (HE). The prepared specimens were observed for their morphology 
using an optical microscope (DMWBI-223 Digital Biological Microscope, Shimadzu 
Corporation). 
Nile Red Staining. Cryosectioned skin samples were treated with Nile red in acetone 
solution (500 mg/mL) with 4% potassium hydroxide solution (Sheu et al., 2003). After 200 
preparing the specimen, it was observed using a confocal laser scanning microscope (CLSM) 
(Fluoview FV1000 and software: FV10-ASW, Olympus, Tokyo, Japan) for the observation 
of neutral fat in the stratum corneum. The CLSM conditions were as follows: wavelength, 
10 
473 nm; scan speed, 200µ/pix; laser power, 1%; high voltage, 236 V; gain, 1.125×; and offset, 
0. 205 
3.0 Statistical Analysis 
All experimental data were tested for statistical significance (p = 0.05) using Student’s 
t-test. 
 
3. RESULTS 210 
3.1 In Vitro Skin Permeation Parameters 
In vitro skin permeation experiments were conducted, and the time courses of 
cumulative amount of drug permeation were determined in order to compare the permeation 
of six model compounds (antipyrine, diclofenac sodium, pilocarpine hydrochloride, 
aminopyrine, tranilast, and lidocaine) with different lipophilicities (log Ko/w) (Table 1) 215 
through eyelid and abdominal skin. Figure 2 shows the results. Typical lag time and 
following steady state permeation were found to be independent of the drug and skin site. In 
addition, drug permeation through the eyelid skin was higher than through the abdominal skin 
independent of the lipophilicity of the applied drugs. Table 3 summarizes the permeation 
fluxes and permeability coefficients that were calculated from the skin permeation profiles. 220 
These permeation parameters were much higher for all model compounds administered via 
the eyelid skin compared with the abdominal skin. In addition, significant differences in the 
fluxes and permeability coefficients were observed for all model compounds when 
comparing eyelid and abdominal skin. Furthermore, 11-fold higher tranilast permeation was 
observed in the eyelid skin than in the abdominal skin. 225 
3.2 Drug Concentration in Skin 
Among the model compounds, drug concentrations in skin were evaluated with 
tranilast and pilocarpine hydrochloride, which are important ophthalmic medications for 
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patients with allergic disease and glaucoma, respectively. Figure 3 shows the result of drug 
concentrations in the whole skin and viable epidermis and dermis (VED) skin after topical 230 
application of these drugs on the eyelid and abdominal skins. Drug concentrations of tranilast 
and pilocarpine in the whole and VED skins in the eyelid skin were higher than those in the 
abdominal skin. Significant differences in pilocarpine were observed in the whole and VED 
skins between the eyelid and abdominal skins, whereas for tranilast concentration, the VED 
showed a significant difference. An approximately 3.7-fold higher pilocarpine concentration 235 
was observed in whole skin and VED, whereas approximately 1.4- and 2.8-fold higher 
tranilast concentrations were confirmed in whole and VED skins, respectively.  
3.3 Histomorphological Evaluation of Under Eyelid and Abdominal Skin 
With interesting results showing high in vitro permeation profiles of hydrophilic and 
lipophilic drugs through the eyelid skin, further evaluation was conducted with impedance, 240 
morphology, and neutral fat content/distribution of the eyelid and abdominal skins in hairless 
rats. Skin impedances of the intact eyelid and abdominal skins were much higher than those 
of stratum corneum-stripped skins. Intact abdominal skin had impedance values of 0.94 ± 
0.20, 0.88 ± 0.19, 0.85 ± 0.16, 0.85 ± 0.15 at 0 min, 15 mins, 30 mins, and 1 h, respectively, 
from the start of the experiment. On the other hand, intact eyelid skin has impedance values 245 
of 0.49 ± 0.18, 0.47 ± 0.17, 0.45 ± 0.16, 0.39 ± 0.17 at 0 min, 15 mins, 30 mins, and 1 h, 
respectively. The values of skin impedance in the intact skins decreased at the beginning of 
the application period, and then the values became constant about 1 h thereafter. Furthermore, 
the abdominal skin had approximately 2-fold higher impedance over 8 h compared with the 
eyelid skin. 250 
HE staining revealed that the stratum corneum in the abdominal skin was denser 
compared with the eyelid skin (Fig. 4). Moreover, Nile red staining images of the stratum 
corneum (the area surrounded by a white line in Fig. 5) indicated that neutral fat in the 
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stratum corneum of the eyelid skin was evidently thinner and less compact compared with the 
abdominal skin. 255 
3.4 In Vivo Eyelid Percutaneous Absorption Studies 
With the concept of administering drugs to the conjunctiva through the eyelid skin, in 
vivo absorption studies were conducted with rhodamine B and fluorescein sodium salt as a 
lipophilic and a hydrophilic model dye compound, respectively. Figure 6 shows the drug 
distribution in skin after application of its solution in eye drops or through the (lower) eyelid 260 
skin. The presence of rhodamine B and fluorescein sodium administered as eye drops was 
markedly observed in the conjunctiva, as indicated by the fluorescence in the images 10 min 
after administration, whereas these were absent at 2 and 8 h. For topical administration onto 
the eyelid skin, a stronger intensity of the fluorescence given off by the model compounds 
was observed over time, which indicated greater amounts of the dye compound in the 265 
conjunctiva. 
 
4. DISCUSSION 
The delivery of ophthalmic medications still remains a challenge. Bioavailability for 
eye drops is poor, amounting to at best 10% of the applied dose, because the eye is protected 270 
by a series of complex defense mechanisms that hinder the achievement of an effective drug 
concentration within the target tissue of the eye. Frequent instillations of eye drops are often 
required to achieve the expected therapeutic benefit, which is inconvenient and often 
associated with adverse effects. (Li et al., 2008; Gan et al., 2010; Wang et al., 2011; Kumar 
and Sinha, 2016; Akhter et al., 2016). On the other hand, transdermal drug delivery systems 275 
offers greater patient comfort while allowing a constant supply of drug at the application site 
and thus provide superior pharmacokinetic profiles. A few studies have reported the 
usefulness of drug permeation through the eyelid skin (Kimura et al., 2007, Isowaki et al., 
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2003) and evaluated drug concentrations in the conjunctiva in in vivo experiments. However, 
no reports have been published on the influence of drug lipophilicity on (lower) eyelid skin 280 
permeation and its comparison between eyelid and abdominal skin permeation. Thus, in the 
present study, drug delivery within the ocular region through the eyelid skin was investigated 
with several drugs that have a wide range of lipophilicity. 
In order to demonstrate the proposed idea of administering medications through the 
eyelid skin, in vitro skin permeation and drug concentration in the eyelid VED skin were 285 
evaluated. Considering that sufficient human skin for a large number of skin permeation 
studies was usually unavailable because of ethical issues, hairless rat skin was used in this 
study. Moreover, hairless rats are easy to handle and manipulate (i.e. docile behavior), hence 
this was the most feasible animal to test the concept of delivering drugs to the conjunctiva via 
the eyelid skin. Several reports have been published that hairless rat skin is a good alternative 290 
for human skin membrane to evaluate skin permeation profiles and permeability coefficients 
of drugs from aqueous solutions (Watanabe et al., 2011; Morimoto et al., 1992; Abd et al., 
2016; and Jung et al., 2014). Skin permeation profiles of several model drugs through the 
excised rat skin were measured to determine their fluxes and permeability coefficients in this 
study. Among various skin regions of the hairless rat, abdominal skin has often been used to 295 
evaluate skin permeation of drugs. Thus, skin permeation of model compounds was 
compared with hairless rat eyelid and abdominal skins to elucidate features in the skin 
permeation of drugs through (lower) eyelid skin.  
Because topically applied drugs are mostly absorbed into the systemic circulation 
through the cutaneous vessels, prolonged retention of the drugs might be difficult below the 300 
application site. In normal (healthy) skin, 97–98% of drugs that penetrate through the stratum 
corneum are taken into the microcirculation located beneath the basal layer of the epidermis 
(Kimura et al., 2007). However, the possibility of direct transport of drugs to the conjunctiva 
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after topical skin application should be evaluated using in vitro permeation experiments, 
because skin permeation and concentration could be calculated with Fick’s second law of 305 
diffusion model (Sugibayashi et al., 2010). 
The ratio or fraction of topically applied drugs that penetrate into the systemic 
circulation or the deeper cutaneous or subcutaneous tissue using an in situ experimental 
model in hairless rats were determined in our previous study (Sugibayashi et al., 1999; 
Hasegawa et al., 2007). Most of the drug fraction that penetrated the skin after topical 310 
application was taken up by the cutaneous blood flow, whereas some directly migrated into 
deeper tissues such as the subcutis and muscle. In our previous study, topical application 
resulted in high drug concentrations in the subcutis and surrounding tissues. Thus, high drug 
concentrations in the conjunctiva can be obtained by topical application through the eyelid 
skin. 315 
Percutaneous absorption of drug molecules is of particular importance in the case of 
transdermal drug delivery systems, and they should be able to cross the permeability barrier 
of the skin, namely the stratum corneum. Moreover, the lipids of the stratum corneum are 
important regulators against skin permeability of topically applied drugs (Feingold, 2009; 
Pappas, 2009). Morphological differences in the various anatomic sites of skin exist. Ya-Xian 320 
Z et al. (1999) reported that variations in the number of cell layers of the stratum corneum 
was observed according to the anatomical location of human skin. The number of stratum 
corneum layers in the eyelid was 8 ± 2 (n=16, mean ± SD), but the abdomen had 14 ± 4 
(n=44, mean ± SD), and a significantly higher transepidermal water loss (TEWL) value was 
observed in the eyelid compared with the abdominal skin. In addition, Pratchyapruit et al. 325 
(2007) reported that eyelid showed a high TEWL value similar to other facial skin. The skin 
surface hydration was as high as that of adjacent skin regions even though the eyelid skin has 
extremely low amounts of surface lipids, unlike its neighboring skin regions. The present 
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results obtained from skin impedance and HE staining also corresponded with these reports. 
Moreover, based on our experimental results, the stratum corneum of eyelid skin had a lower 330 
neutral fat content. These results supported our findings, in which a significant difference was 
observed between the permeability coefficient of the model compounds through the eyelid 
skin compared with the abdominal skin. In terms of the relationship between molecular 
weight and logP, a strong positive relationship exists. Many reports have been published on 
the relationship of MW and log Ko/w on skin permeation through abdominal skin (Morimoto et 335 
al., 1992; Potts and Guy, 1992; Chen et al., 2013). Although there is a regional difference in 
the skin permeation of drugs, skin permeation of drugs through eyelid skin would be 
expressed with a function of MW and log Ko/w. In the present experiment, only several drugs 
were used to compare the skin permeation differences between abdominal and lower eyelid 
skins. Thus, it was difficult to explain the effect of these parameters on the skin permeation of 340 
drugs through eyelid skin. 
To further confirm drug delivery via the eyelid skin into the conjunctiva, in vivo 
experiments were performed with the fluorescent markers rhodamine B and fluorescein 
sodium salt. The disposition of these model compounds in the conjunctiva increased with the 
passage of time. The intensity of fluorescence at 8 h after administration via the eyelid skin 345 
was markedly higher than that of eye drop administration. There was no fluorescence 
observed at 2 h after eye drop administration, indicating the absence or very low distribution 
of the model compounds in the conjunctiva. The present results correspond with a study 
utilizing conventional eye drops, which resulted to lower bioavailability (Lux et al., 2003). 
Rapid and extensive loss caused by drainage and high tear fluid turnover of the instilled eye 350 
drops may be the main reason for the disappearance of the fluorescence within 2 h after 
administration. Moreover, the contact time of the model compound with ocular tissues was 
relatively short because of the constant production of lacrimal fluid. In contrast, transdermal 
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drug delivery through eyelid offers a steady concentration of the model compound for an 
extended period of time. This further supports the findings of our in vivo absorption studies 355 
wherein fluorescence were evident even after 8 h while being unnoticeable for eye drops. We 
have confirmed the migration of the model drugs from the eyelid skin into the conjunctiva 
and eyeball. Although drug concentration and its distribution profile into the eyeball is not 
reported in this study, a preliminary study revealed that administration of model compounds 
via the eyelid skin were detected in eyeball homogenates, suggesting the possibility of drug 360 
delivery into the conjunctiva and eyeball. The mechanism of drug migration from eyelid skin 
to the eyeball has not yet been determined. Currently, we assume that drug partitioning from 
eyelid skin to lacrimal fluid was the primal route for drug migration into the eyeball. 
There is a need to address the bioavailability and the delivery of drugs applied on the 
eyelid skin and as eye drops. The bioavailability resulting from eye drop administration is 365 
presumed to be very low. In this study, the permeability coefficient of drugs applied onto 
eyelid skin was much higher than that of abdominal skin. The obtained permeability 
coefficients from the lowest (3.66 ± 1.25 × 10-7 cm/s for tranilast) to the highest (151 ± 11.8 
× 10-7 cm/s for lidocaine) (Table 3) are similar or higher than those drugs that are already 
marketed as transdermal delivery systems. The targeting ability of eye drops to the 370 
conjunctiva is high because of its direct contact with the conjunctiva. However, its 
elimination is high, and at the same time the drug concentration in the conjunctiva may not be 
sustained (see Fig. 6). Despite lacking direct contact with the conjunctiva, eyelid 
administration as a delivery method exhibited an advantage of having controlled drug 
delivery, as shown in Fig. 6. 375 
The eyelid skin is known to be thinner than the conventional skin administration sites, 
and it offers higher drug permeation, as demonstrated by the results of this study. Developing 
formulations dedicated to eyelid administration such as an eyelid patch is recommended. In 
17 
fact, ointments are often used for night time application but are associated with discomfort 
due to greasiness, tear film instability, and uncertain drug disposition after eye shutting while 380 
asleep (Desai and Lee, 2007). Thus, eyelid skin application is seen to be beneficial even 
during sleep when the use of liquid and semi-solid eye preparations is deemed impossible. 
 
5. CONCLUSION 
The drug concentration in rat conjunctiva after application on the eyelid skin was 385 
higher than that of conventional eye drops. In addition, drug permeation through eyelid skin 
was higher than that through abdominal skin regardless of lipophilicity. Diclofenac sodium 
salt and tranilast significantly showed higher permeation coefficients than abdominal skin of 
about 6-fold and 11-fold, respectively. With these preliminary findings, eyelid skin is 
considered to be a promising site for the administration of ophthalmic drugs. Further in vivo 390 
studies will be needed to establish the distribution of drugs in various parts of the ocular 
regions after eyelid administration.  
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Table 1. Physicochemical properties of chemicals used in the study 
Chemical Molecular weight Log Ko/w 
Antipyrine 188.23 -1.51 
Diclofenac sodium salt 318.13 -0.96 
Fluorescein sodium salt 376.28 -0.61 
Pilocarpine 208.26 0.17 
Aminopyrine 231.29 1.07 
Tranilast 327.33 1.80 
Rhodamine B 479.02 2.28 
Lidocaine  234.33 2.37 
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Table 2. HPLC conditions for analysis of chemicals used in the study 
Chemical Mobile phase Detection wavelength (nm) Internal standard 
Aminopyrine 
Acetonitrile:0.1% phosphoric 
acid containing 5 mM sodium 
dodecylsulphonate = 40:60 
245 p-hydroxybenzoic acid methyl ester 
Antipyrine Acetonitrile:water = 20:80 254 ---a 
Diclofenac 
Na 
Methanol:0.1% phosphoric 
acid = 80:20 286 
p-hydroxybenzoic 
acid ethyl ester 
Lidocaine 
Acetonitrile:0.1% phosphoric 
acid containing 5 mM 1-
heptanesulphonate = 35:65 
245 p-hydroxybenzoic acid n-propyl ester 
Pilocarpine 
Acetonitrile:0.1% phosphoric 
acid = 5:95 212 ---
a 
Tranilast Acetonitrile:0.1% phosphoric acid = 40:60 230 
p-hydroxybenzoic 
acid ethyl ester 
a Absolute calibration curve method was used 
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Table 3. Flux and permeability coefficient of model compounds 
  Eyelid Abdominal  
Chemical Flux 
(µg/cm2/h) 
 
Permeability 
coefficient 
(×10-7cm/s) 
Flux 
(µg/cm2/h) 
 
Permeability 
coefficient 
(×10-7cm/s) 
Enhancement 
ratio (Peyelid/P 
abdominal) 
Antipyrine#, - 150 ± 13.9 8.36 ± 0.77 66.5 ± 7.23 3.69 ± 0.40 2.3 
Diclofenac 
sodium salt #, - 72.2 ± 21.7 4.01 ± 1.20 12.0 ± 3.23 0.67 ± 0.18 6.0 
Pilocarpine#, - 24.3 ± 4.95 49.1 ± 7.28 8.27 ± 1.63 18.8 ± 3.70 2.6 
Aminopyrine#, - 745 ± 146 69.0 ± 13.6 335 ± 59.7 31.0 ± 5.53 2.2 
Tranilast#,- 0.64 ± 0.23 3.66 ± 1.25 0.05 ± 0.02 0.34 ± 0.13 11 
Lidocaine#, - 179 ± 14.0 151 ± 11.8 40.3 ± 10.6 34.2 ± 8.94 4.4 
Significant difference (P<0.05) between eyelid and abdominal for fluxes (#) and for 
permeability coefficients(-) 
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Figure 1. Illustration for in vivo absorption study 405 
 
Figure 2. Time course of the cumulative amount of hydrophilic and lipophilic model drugs, A)	
antipyrine, B)	 diclofenac sodium, C)	 pilocarpine hydrochloride, D)	 aminopyrine, E)	
tranilast, F)	lidocaine through eyelid (●) and abdominal (▲) skin. Each value represents a 
mean ±S.E. (n=3–5) 410 
 
Figure 3. Skin concentration profile of pilocarpine (A) and tranilast (B) model compound in 
eyelid (□) and abdominal skin (■). Each value represents a mean ±S.E. (n=3). *p<0.05 
Figure 4. HE staining images of hairless rat skin. (A) abdominal skin; (B) eyelid skin. 
Magnification 400× 415 
Figure 5. Nile red staining images of neutral lipids in stratum corneum of hairless rat skin 
enclosed in white box. (A) eyelid skin; (B) abdominal skin. Magnification 800× 
Figure 6. Photomicrographs of rat eyelid skin under CLSM after in vivo absorption studies. 
Transmission Images (A1–L1); Confocal laser scanning images (A2–L2) 
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